| Symbol | VXLLF |
|---|---|
| Name | VAXIL BIO LTD. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | M5N 1N1 Canada ON 559 Briar Hill Avenue |
| Telephone | — |
| Fax | — |
| — | |
| Website | https://vaxil-bio.com/ |
| Incorporation | CA |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: TSX Venture Exchange |
| CIK | — |
| Description | Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company develops ImMucin, a MUC1 SP-derived vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. It is also developing SP-based COVID-19 and tuberculosis vaccine/treatment candidate. Additional info from OTC: |
No news found.